Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Postal Ballot Notice Dated 10Th February, 2022

 With reference to our intimation dated 10th February, 2022 and pursuant to Regulation 30 of the SEBI Listing Regulations, 2015, we enclose herewith a copy of Postal Ballot Notice for the following Special Resolution proposed to be passed by the members only by way of remote e-voting: 1. Appointment of Mr. Ashok Barat (DIN: 00492930) as an Independent Director of the Company. We request you to kindly take the same on record.
11-02-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Postal Ballot Notice Dated 10Th February, 2022

 With reference to our intimation dated 10th February, 2022 and pursuant to Regulation 30 of the SEBI Listing Regulations, 2015, we enclose herewith a copy of Postal Ballot Notice for the following Special Resolution proposed to be passed by the members only by way of remote e-voting: 1. Appointment of Mr. Ashok Barat (DIN: 00492930) as an Independent Director of the Company. We request you to kindly take the same on record.
11-02-2022

Earnings Call for Q3FY22 of Alembic Pharmaceuticals

 Conference Call with Alembic Pharmaceuticals Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.
10-02-2022

Price erosion in US drags Alembic Pharma's Q3 net down 40% to Rs 176 cr

 While the firm's US business fell 23% to Rs 393 cr in Q3FY22, its API sales were down 7% to Rs 198 crore
10-02-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Appointment Of Independent Director

 With reference to the captioned matter, this is to inform the exchange that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors at its meeting held on 10th February, 2022 has approved the appointment of Mr. Ashok Barat (DIN: 00492930) as an Independent Director of the Company for a period of 5 (five) consecutive years w.e.f. 10th February, 2022, subject to approval of the members by way of a Special Resolution. The Board has approved the Postal Ballot Notice and decided Friday, 11th February, 2022 as cut-off date to determine name of the members who are entitled to receive the said Notice and vote on the resolution. A copy of the Postal Ballot Notice will be submitted vide a separate communication in due course. We hereby declare that Mr. Ashok Barat is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. We request you to kindly take the same on record.
10-02-2022
Bigul

Q3FY22 Quarterly Result Announced for Alembic Pharmaceuticals Ltd.

 Alembic Pharmaceuticals declares Q3FY22 result: Net Sales for the quarter at Rs 1272 crores. Net Profit for the quarter at Rs 176 crores. Net sales for 9M FY22 at Rs 3890 crores. Net profit for 9M FY22 at Rs 510 crores. Mr. Shaunak Amin, Managing Director, Al.embic Pharmaceuticals Limited said "India Branded business has posted a strong growth rate for the third consecutive quarter. Strong operational performance is attributed to consistent efforts of team and strengthening of customer relationships. Branded business witnessed market outperforming growth across most of the key products and therapy areas." Result PDF
10-02-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Unaudited Financial Results For The Quarter And Nine Months Period Ended 31St December, 2021.

 Unaudited Financial Results for the quarter and nine months period ended 31st December, 2021. Please find enclosed herewith standalone and consolidated financial results of the Company for the quarter and nine months period ended 31st December, 2021, Press Release and Investor Presentation.
10-02-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board Meeting Outcome for Outcome Of Board Meeting

 With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia approved the: 1. Unaudited Financial Results for the quarter and nine months period ended 31st December, 2021. 2. Appointment of Mr. Ashok Barat (DIN: 00492930) as an Independent Director of the Company w.e.f. 10th February, 2022. The detailed disclosures is being submitted vide a separate communication. Please find enclosed herewith standalone and consolidated financial results of the Company for the quarter and nine months period ended 31st December, 2021, Press Release and Investor Presentation. The time of commencement of the Board Meeting was 12:30 p.m. and the time of conclusion was 2:00 p.m. We request you to kindly take the same on record.
10-02-2022

Alembic Pharma gets tentative USFDA nod for fesoterodine fumarate extended-release tablets

 The approval by the US Food Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for fesoterodine fumarate extended-release tablets is for strengths of 4 mg and 8 mg, the company said in a statement.
02-02-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.
02-02-2022
Next Page
Close

Let's Open Free Demat Account